Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
An update from Genflow Biosciences Plc ( (GB:GENF) ) is now available.
Genflow Biosciences Plc has signed a Master Service Agreement with CER Groupe to enhance their long-term R&D collaboration, focusing on accelerating Genflow’s pre-IND gene therapy programs. This agreement aims to streamline project management and leverage scientific expertise to drive innovation and ensure scientific outcomes, potentially strengthening Genflow’s operational alignment and strategic agility in the biotechnology industry.
More about Genflow Biosciences Plc
Genflow Biosciences Plc, founded in 2020 and headquartered in the UK with R&D facilities in Belgium, is a biotechnology company focused on pioneering gene therapies to slow the aging process. Its lead compound, GF-1002, targets the SIRT6 gene and is currently undergoing a 12-month clinical trial in aged dogs. The company also plans to explore GF-1002’s potential in treating MASH, a prevalent chronic liver disease.
Average Trading Volume: 2,679,913
Technical Sentiment Signal: Sell
For an in-depth examination of GENF stock, go to TipRanks’ Stock Analysis page.